Takeda Exercises Option to Acquire PvP Biologics

By Michelle Liu

Pharma Deals Review: Vol 2020 Issue 3 (Table of Contents)

Published: 7 Mar-2020

DOI: 10.3833/pdr.v2020.i3.2519     ISSN: 1756-7874

Section: Mergers & Acquisitions



Triggered by a Phase I data read out for TAK-062, Takeda Pharmaceutical has exercised an option given to it as part of a 2017 agreement to acquire PvP Biologics...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details